Kazatomprom Reports 17 Production Increase in Q3 2025 SEBI Bars Seven Entities for Social MediaDriven Stock Manipulation Freezes 20 Crore Gains Prediction Market Investments Continue Despite Regulatory Uncertainty Monetarism Compared to Soviet Central Planning A Critical Economic Perspective The Pitfalls of Chasing Returns Why Investors Should Focus on LongTerm Strategy Trump Claims Iran Deal to Reopen Strait of Hormuz Largely Negotiated Fortrea Holdings Inc FTRE Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction GCBC Q2 2025 Earnings Solid EPS Performance Amid Steady Banking Operations EDUC Q1 2026 Earnings Narrowing Loss Highlights Ongoing Restructuring ASND Q1 2026 Earnings EPS Misses Estimates as Ascendis Pharma Navigates Cost Pressures CZFS Q1 2026 Earnings EPS Beats Estimates by 695 as Solid Core Performance Offsets Market Uncertainty BTCT Q4 2024 Earnings Surprise Profitability Despite Revenue Absence Crane Harbor Acquisition Corp Units CHACU Tumble Over 10 Key Support Tested Amid Selling Pressure Aebi Schmidt Holding Gains 2 as Shares Approach Key Resistance Level Tevogen Bio Holdings TVGN Slides 105 as Selling Pressure Intensifies Progressive Corporation PGR Edges Higher as Shares Hold Near Key Support Levels Sunstone Hotel Investors SHO Edges Lower Navigating a Cautious Hospitality Landscape Silver Price Outlook Key Factors That Could Shape the Next Decade AmeriServ Financial Inc ASRV Q1 2026 Earnings Modest Profit Amid Flat Revenue Environment JX Luxventure Group Inc JXG Gains 478 as Shares Test Key Resistance Near 759 Cheche Group Inc Q4 2024 Earnings NarrowerThanExpected Loss as Stock Slips Kyntra Bio Inc KYNB Q1 2026 Earnings PreRevenue Biotech Misses EPS Estimates as Stock Edges Higher NVAX Q1 2026 Earnings Surprise EPS Beat Amidst Revenue Disruption KRRO Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Surprise Despite No Revenue Ingram Micro Holding Corporation INGM Q1 2026 Earnings Earnings Beat Driven by Operational Efficiency LCTX Q1 2026 Earnings WiderthanExpected Loss as ClinicalStage Biotech Reports No Revenue TEVA Q1 2026 Earnings EPS Beats Estimates by 878 as Generic Drugmaker Posts Strong Quarter